Status:
ACTIVE_NOT_RECRUITING
Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair
Lead Sponsor:
Assiut University
Conditions:
Complication Following Peripheral Nerve Block
Eligibility:
All Genders
12-7 years
Brief Summary
The aim of this study is to evaluate the efficacy of adding nalbuphine to bupivacaine via suprazygomatic nerve block for postoperative pain control and emergence agitation management in pediatrics age...
Detailed Description
Cleft lip and cleft palate are the most common craniofacial abnormalities in children. Cleft surgery results in a profound sympathetic stimulation leading to hypertension, tachycardia, and bleeding. P...
Eligibility Criteria
Inclusion
- Age 1 to 7 years.
- Both genders.
- American society of anesthesiologists (ASA) physical state I-II.
- Children undergoing palate surgeries.
Exclusion
- Guardians' refusal
- History of developmental delay or mental retardation.
- Children with any co-morbidities.
- Skin infection at the site of injection.
- Bleeding diathesis.
- Known allergy to any drugs used in this study.
Key Trial Info
Start Date :
July 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06100315
Start Date
July 31 2023
End Date
January 1 2026
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed Fathy Mostafa
Asyut, Egypt